Retinal Physician presents the latest news on industry and clinical research into therapies for retinal diseases.
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
VEGF-C and VEGF-D are innately involved in the neovascular etiology, so treating that component, in addition to traditional anti-VEGF-A treatment, may have the potential for…
Dr. Tadayoni was well known internationally for his leadership in retinal surgery and ophthalmic education, and he was a revered mentor and friend.
Atsena Therapeutics has announced that dosing has begun for the second cohort in LIGHTHOUSE, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201, a…
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Polymeric technologies have the potential to revolutionize the intravitreal treatment approach for retinal diseases.
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Monthly or bimonthly anti-VEGF use poses significant time and cost burden due to the disease’s chronic nature and limited medication half-life. Further potential solutions to…
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
